The development of COVID-19 vaccines in the United States: Why and how so fast?
作者信息
Kuter Barbara J, Offit Paul A, Poland Gregory A
机构信息
Vaccine Education Center, Children's Hospital of Philadelphia, United States.
Mayo Clinic, Rochester, MN, United States.
出版信息
Vaccine. 2021 Apr 28;39(18):2491-2495. doi: 10.1016/j.vaccine.2021.03.077. Epub 2021 Mar 26.
Abstract
摘要
相似文献
1
The development of COVID-19 vaccines in the United States: Why and how so fast?美国新冠疫苗的研发：为何如此迅速，又是如何做到的？
Vaccine. 2021 Apr 28;39(18):2491-2495. doi: 10.1016/j.vaccine.2021.03.077. Epub 2021 Mar 26.
2
The race to make a COVID-19 vaccine.新冠疫苗的研发竞赛。
Lancet. 2021 Sep 4;398(10303):832-833. doi: 10.1016/S0140-6736(21)01902-4.
3
Fast Development of High-Quality Vaccines in a Pandemic.大流行期间高质量疫苗的快速研发
Chest. 2021 Jul;160(1):e1-e3. doi: 10.1016/j.chest.2021.03.063. Epub 2021 Apr 20.
4
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
5
Status of vaccine development for COVID-19.2019冠状病毒病疫苗的研发现状。
Br J Community Nurs. 2020 Dec 2;25(12):620-621. doi: 10.12968/bjcn.2020.25.12.620.
6
Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited!为什么不存在新冠疫苗？制药行业的科学情报和商业模式必须重新审视！
Expert Opin Drug Discov. 2020 Nov;15(11):1233-1235. doi: 10.1080/17460441.2020.1777980. Epub 2020 Jun 16.
7
The Covid-19 Vaccine-Development Multiverse.新冠疫苗研发多元世界。
N Engl J Med. 2021 Feb 18;384(7):681-682. doi: 10.1056/NEJMc2034838. Epub 2021 Jan 27.
8
Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.COVID-19 疫苗研发的进展与挑战及对 SARS-CoV-2 特异性免疫应答的现有认识。
J Microbiol Biotechnol. 2020 Aug 28;30(8):1109-1115. doi: 10.4014/jmb.2006.06006.
9
Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.信使 RNA 新冠病毒 2019 疾病（COVID-19）疫苗对医护人员队列中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性。
Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379. doi: 10.1093/cid/ciab361.
10
Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.开发安全有效的新冠疫苗——“极速行动”计划的策略与方法。
N Engl J Med. 2020 Oct 29;383(18):1701-1703. doi: 10.1056/NEJMp2027405. Epub 2020 Aug 26.
引用本文的文献
1
De-risking vaccine development: lessons, challenges, and prospects.降低疫苗研发风险：经验教训、挑战与前景。
NPJ Vaccines. 2025 Jul 30;10(1):177. doi: 10.1038/s41541-025-01211-z.
2
Development, launch, and scale-up of health products in low-income and middle-income countries: a retrospective analysis on 59 health products.低收入和中等收入国家卫生产品的研发、推出及推广：对59种卫生产品的回顾性分析
Lancet Glob Health. 2025 Jun;13(6):e1132-e1139. doi: 10.1016/S2214-109X(25)00062-2.
3
The future of pandemic modeling in support of decision making: lessons learned from COVID-19.支持决策的大流行建模的未来：从 COVID-19 中吸取的教训。
BMC Glob Public Health. 2025 Mar 25;3(1):24. doi: 10.1186/s44263-025-00143-z.
4
Demographic disparities in access to COVID-19 clinical trial sites across the United States: a geospatial analysis.美国各地获得COVID-19临床试验地点的人口统计学差异：一项地理空间分析。
Int J Equity Health. 2025 Jan 23;24(1):26. doi: 10.1186/s12939-024-02360-8.
5
Geospatial analysis of contagious infection growth and cross-boundary transmission in non-vaccinated districts of North-East Indian states during the COVID-19 pandemic.新冠疫情期间印度东北部各邦未接种疫苗地区传染性感染增长及跨境传播的地理空间分析
Lancet Reg Health Southeast Asia. 2024 Jul 19;28:100451. doi: 10.1016/j.lansea.2024.100451. eCollection 2024 Sep.
6
COVID-19 clinical trial participation and awareness in Texas.德克萨斯州的新冠病毒疾病（COVID-19）临床试验参与情况与认知度
Hum Vaccin Immunother. 2024 Dec 31;20(1):2340692. doi: 10.1080/21645515.2024.2340692. Epub 2024 Apr 24.
7
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.在撒哈拉以南非洲队列中，对 Moderna 的 mRNA-1273 疫苗的持续 S-IgG 和 S-IgA 抗体表明需要重新考虑加强针的时间。
Front Immunol. 2024 Jan 31;15:1348905. doi: 10.3389/fimmu.2024.1348905. eCollection 2024.
8
Therapeutics to Treat Psychiatric and Neurological Disorders: A Promising Perspective from Algerian Traditional Medicine.治疗精神和神经疾病的疗法：来自阿尔及利亚传统医学的一个有前景的视角。
Plants (Basel). 2023 Nov 15;12(22):3860. doi: 10.3390/plants12223860.
9
Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases.比较 18 种疫苗的研发、上市和扩大规模的时间表：从 COVID-19 中吸取的经验教训及其对其他传染病的影响。
BMJ Glob Health. 2023 Sep;8(9). doi: 10.1136/bmjgh-2023-012855.
10
Vaccine Equity: Lessons Learned Exploring Facilitators and Barriers to COVID-19 Vaccination in Urban Black Communities.疫苗公平性：探索城市黑人社区 COVID-19 疫苗接种促进因素和障碍的经验教训。
J Racial Ethn Health Disparities. 2024 Aug;11(4):2109-2119. doi: 10.1007/s40615-023-01680-9. Epub 2023 Jun 30.
本文引用的文献
1
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.美国 2020 年 12 月 21 日-2021 年 1 月 10 日期间，在接种 Moderna COVID-19 疫苗第一针后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.
2
Looking beyond COVID-19 vaccine phase 3 trials.展望 COVID-19 疫苗 III 期临床试验之外。
Nat Med. 2021 Feb;27(2):205-211. doi: 10.1038/s41591-021-01230-y. Epub 2021 Jan 19.
3
Vaccinating the UK: how the covid vaccine was approved, and other questions answered.为英国接种疫苗：新冠疫苗是如何获批的及其他问题解答
BMJ. 2020 Dec 9;371:m4759. doi: 10.1136/bmj.m4759.
4
Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.新冠疫苗的紧急使用授权——安全性和有效性随访考量
N Engl J Med. 2020 Nov 5;383(19):e107. doi: 10.1056/NEJMp2031373. Epub 2020 Oct 16.
5
COVID-19 vaccine trials should seek worthwhile efficacy.新冠病毒疫苗试验应追求有价值的疗效。
Lancet. 2020 Sep 12;396(10253):741-743. doi: 10.1016/S0140-6736(20)31821-3. Epub 2020 Aug 27.
6
Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.开发安全有效的新冠疫苗——“极速行动”计划的策略与方法。
N Engl J Med. 2020 Oct 29;383(18):1701-1703. doi: 10.1056/NEJMp2027405. Epub 2020 Aug 26.
7
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times.加速COVID-19治疗干预和疫苗（ACTIV）：应对前所未有的时代的前所未有的合作。
JAMA. 2020 Jun 23;323(24):2455-2457. doi: 10.1001/jama.2020.8920.
8
A strategic approach to COVID-19 vaccine R&D.一种应对新冠病毒疫苗研发的战略方法。
Science. 2020 May 29;368(6494):948-950. doi: 10.1126/science.abc5312. Epub 2020 May 11.
9
The race for coronavirus vaccines: a graphical guide.新冠疫苗竞赛：图解指南
Nature. 2020 Apr;580(7805):576-577. doi: 10.1038/d41586-020-01221-y.
10
The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century.21 世纪出现的严重急性呼吸综合征（SARS）、中东呼吸综合征（MERS）和新型严重急性呼吸综合征冠状病毒（SARS-CoV-2）。
Arch Virol. 2020 Jul;165(7):1517-1526. doi: 10.1007/s00705-020-04628-0. Epub 2020 Apr 22.
Zotero 插件